Presentation is loading. Please wait.

Presentation is loading. Please wait.

The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place ? Paul M. Tulkens Cellular and Molecular.

Published byDaisy Lester Modified over 6 years ago

Similar presentations

Presentation on theme: "The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place ? Paul M. Tulkens Cellular and Molecular."— Presentation transcript:

1 The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place ? Paul M. Tulkens Cellular and Molecular Pharmacology Unit Catholic University of Louvain, Brussels, Belgium Founding member and past-president ( ) of ISAP PK/PD - ICC - Manila, June 5th, 2005

2 The situation in the early 90's …
anti-infective drug doising was largely irrational or not based on sounds pharmacodynamics / toxicodynamics search for low doses for fear of toxicity “errors” in drug dosages at registration misunderstanding of what is an optimal schedule and what it implies pharmacokinetics was mainly used to establish “drug presence” rather than to make true correlations with efficacy PK/PD - ICC - Manila, June 5th, 2005

3 PK/PD of antiinfectives : what has been done ?
Over the last 10 years, three major concepts have emerged and proven useful : dose-effect relationships are not the same for all anti-infectives beta-lactams vs. fluoroquinolones or aminoglycosides integration of PK/PD within pre-clinical and early clinical development allows prediction of success or failure of new antimicrobials PK/PD may help in preventing the emergence of resistance PK/PD - ICC - Manila, June 5th, 2005

4 PK /PD in action in the Regulatory in the USA
FDA July 1998 PK/PD - ICC - Manila, June 5th, 2005

5 PK /PD in action in the Regulatory in the USA
FDA November 2002 PK/PD - ICC - Manila, June 5th, 2005

6 PK /PD in action in the Regulatory in Europe
" Inadequate dosing of antibiotics is probably an important reason for misuse and subsequent risk of resistance. A recommendation on proper dosing regimens for different infections would be an important part of a comprehensive strategy. The possibility of approving a dose recommendation based on pharmacokinetic and pharmacodynamic considerations will be further investigated in one of the CPMP* working parties… " * Committee for Proprietary Medicinal Products EMEA July 1999 PK/PD - ICC - Manila, June 5th, 2005

7 Publications of the EMEA ...
PK/PD - ICC - Manila, June 5th, 2005

8 The basis of PK/PD Concentration versus time in tissues and
other body fluids Pharmacologic or toxicologic effect Concentration versus time in serum Dosage regimen Concentration versus time at site of infection Antimicrobial effect versus time absorption distribution elimination PHARMACOKINETICS PHARMACODYNAMICS Craig (1998) CID 26:1-10 PK/PD - ICC - Manila, June 5th, 2005

9 Moving from PK to PD … Pharmacodynamics Pharmacokinetics PK/PD conc .
vs time Conc Time 25 0.0 0.4 PK/PD effect Effect 1 Pharmacodynamics 10 -3 . (log) PK/PD - ICC - Manila, June 5th, 2005

10 Pharmacokinetic/ Pharmacodynamics in Drug Development and Evaluation
The combination of in vitro modelling, proper design of animal model experiments, and the willingness to obtain sparse pharmacokinetic information on patients in clinical trials allows an in depth understanding of which aspects of drug exposure are most closely linked to therapeutic outcome as well as to toxicity. By providing such information to clinicians, drug therapy can achieve the goal of maximal therapeutic effect while engendering the lowest probability of encountering a drug exposure-related adverse event. PK/PD - ICC - Manila, June 5th, 2005

11 Main PK/PD properties of antibiotics
Available antibiotic can be divided in 3 groups time - dependent (T > MIC) AUC / MIC - dependent both AUC / MIC AND peak / MIC -dependent Caveat: this applies to the "clinically-meaningful" concentration window only … PK/PD - ICC - Manila, June 5th, 2005

12 Clinically-meaningful concentration window …
ampicillin gentamicin All antibiotics are concentration-dependent, but it all dependent as how you look at them … Cmin Cmax Cmin Cmax S. aureus; 24 h Barcia-Macay et al, submitted; Lemaire et al (2005) JAC PK/PD - ICC - Manila, June 5th, 2005

13 Antibiotics Group # 1 (after W.A. Craig, 2000; revised 2003)
1. Antibiotics with time-dependent effects and no or little persistent effects AB -lactams PK/PD parameter Time above MIC Goal Maximize the exposure time * 2d ISAP Educational Workshop, Stockholm, Sweden, 2000; revised accord. to Craig Craig, Infect. Dis. Clin. N. Amer., 17: , 2003 PK/PD - ICC - Manila, June 5th, 2005

14 Antibiotics Group # 2 (after W.A. Craig, 2000; revised 2003)
2. Antibiotics with time-dependent effects, with little or no influence of the concentration BUT with persistent effects AB glycopeptides tetracyclines macrolides streptogramines fluconazole PK/PD parameter 24h AUC / MIC ratio Goal Optimize the quantity of AB administered * 2d ISAP Educational Workshop, Stockholm, Sweden, 2000; revised accord. to Craig Craig, Infect. Dis. Clin. N. Amer., 17: , 2003 PK/PD - ICC - Manila, June 5th, 2005

15 Antibiotics Group # 3 (after W.A. Craig, 2000; revised 2003)
3. Antibiotics with concentration-dependent activity and with persistant effects (PAE) AB aminoglycosides fluoroquinolones daptomycin PK/PD parameter Cmax / MIC and 24h AUC / MIC ratios Goal Optimize both the peak and the quantity of drug * 2d ISAP Educational Workshop, Stockholm, Sweden, 2000; revised accord. to Craig Craig, Infect. Dis. Clin. N. Amer., 17: , 2003 PK/PD - ICC - Manila, June 5th, 2005

16 PK / PD in action for the clinics
Some achievements: once-daily dosing of aminoglycosides introduced in many countries amikacin, netilmicin (from bid to qd) isepamicin (registered essentially for qd dosing) 24h AUC / MIC and Cmax / MIC ratios used as guides for phase II / III trials, for treatment optimization and for registration of new antimicrobials moxifloxacin telithromycin dosage of beta-lactams adjusted to cover T > MIC in relation with the expected pathogen… PK/PD - ICC - Manila, June 5th, 2005

17 PK/PD and resistance … PK/PD - ICC - Manila, June 5th, 2005

18 Mutant Prevention Concentration …
Bactericidal effect of a FQ towards Mycobacterium bovis 1 MIC 99 = 0.8 10 -2 "Classic" bactericidal effect 10 -4 Surviving bacteria 10 -6 10 -8 MPC 10 = 9 Elimination of first mutants 10 -10 0.01 0.10 1.00 10.00 concentration Dong et al; AAC 43: PK/PD - ICC - Manila, June 5th, 2005

19 Mutant Prevention Concentration …
Concentration which will inhibit the majority of the organisms 1 MIC 99 = 0.8 10 -2 10 -4 Surviving bacteria Concentration necessary to prevent the selection of the first mutants 10 -6 10 -8 MPC 10 = 9 10 -10 0.01 0.10 1.00 10.00 concentration Dong et al; AAC 43: PK/PD - ICC - Manila, June 5th, 2005

20 "Window" where selection of mutants takes place …
Mutation selection window MPC concentration MSW MIC Time after administration concept from Drlica & Zhao, Rev. Med. Microbiol. 2004, 15:73-80 PK/PD - ICC - Manila, June 5th, 2005

21 "Window" where selection of mutants takes place …
Eradication of the first mutants MPC concentration MSW Selection of the first mutants MIC No therapeutic effect Time after administration concept from Drlica & Zhao, Rev. Med. Microbiol. 2004, 15:73-80 PK/PD - ICC - Manila, June 5th, 2005

22 Therefore, new breakpoints for FQ …
Van Bambeke F, Michot JM, Van Eldere J, Tulkens PM. Quinolones in 2005: an update. Clin Microbiol Infect Apr;11(4): PMID: PK/PD - ICC - Manila, June 5th, 2005

23 Or, correct assessment of telithromycin…
Ery-r But MIC90 for Ery-r strains: Ery-S 100 80 PK/PD limit of sensitivity (0.25 mg/L) 60 % of strains 40 20 0.015 0.03 0.06 0.12 0.25 0.5 1 2 MIC (mg/L) MIC90 for Ery-s strains: < Verhaegen & Verbist, Acta Clin. Belg. 2001, 56: 351 PK/PD - ICC - Manila, June 5th, 2005

24 PK/PD in 2005 … Use if for efficacy …
Consider it for avoiding resistance PK/PD - ICC - Manila, June 5th, 2005

Download ppt "The pharmacological and microbiological basis of PK/PD : why did we need to invent PK/PD in the first place ? Paul M. Tulkens Cellular and Molecular."

Similar presentations

MonteCarlo-Orlando06 - 1 Use of Monte Carlo simulations to select PK/PD breakpoints and therapeutic doses for antimicrobials in veterinary medicine PL.

MonteCarlo-Orlando Use of Monte Carlo simulations to select PK/PD breakpoints and therapeutic doses for antimicrobials in veterinary medicine PL.
Getting the Dose Right The View from Academia

Getting the Dose Right The View from Academia
Animal Model PK/PD: A Tool for Drug Development

Animal Model PK/PD: A Tool for Drug Development
1 PK/PD modeling within regulatory submissions Is it used? Can it be used and if yes, where? Views from industry 24 September 2008.

1 PK/PD modeling within regulatory submissions Is it used? Can it be used and if yes, where? Views from industry 24 September 2008.
Plasmids Chromosome Plasmid Plasmid + Transposon Plasmid + integron Plasmid+transposon +intergron Chromosome Chromosome + transposon Chromosome + transposon.

Plasmids Chromosome Plasmid Plasmid + Transposon Plasmid + integron Plasmid+transposon +intergron Chromosome Chromosome + transposon Chromosome + transposon.
Should we change the recommendations related to antibiotic drug dosage/drug duration? Workshop on Economic Epidemiology Makerere University August, 2009.

Should we change the recommendations related to antibiotic drug dosage/drug duration? Workshop on Economic Epidemiology Makerere University August, 2009.
Office of Drug Evaluation IV, CDER FDA/IDSA/ISAP Workshop 4/16/04 Overview of PK-PD in Drug Development Programs: FDA Perspective FDA/IDSA/ISAP Workshop.

Office of Drug Evaluation IV, CDER FDA/IDSA/ISAP Workshop 4/16/04 Overview of PK-PD in Drug Development Programs: FDA Perspective FDA/IDSA/ISAP Workshop.
Michael R. Jacobs, MD, PhD Professor of Pathology and Medicine Case Western Reserve University Director of Clinical Microbiology University Hospitals of.

Michael R. Jacobs, MD, PhD Professor of Pathology and Medicine Case Western Reserve University Director of Clinical Microbiology University Hospitals of.
Overview of Use of PK-PD in Streamlining Drug Development William A. Craig Professor of Medicine University of Wisconsin.

Overview of Use of PK-PD in Streamlining Drug Development William A. Craig Professor of Medicine University of Wisconsin.
Chapter 10: Restricting antibiotic use and optimizing dosing.

Chapter 10: Restricting antibiotic use and optimizing dosing.
Pharmacodynamics of Antibiotics

Pharmacodynamics of Antibiotics
Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 1 Improvement in Dose Selection: FDA Perspective IDSA/ISAP/FDA Workshop.

Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 1 Improvement in Dose Selection: FDA Perspective IDSA/ISAP/FDA Workshop.
25 MB of information … CONTENT OF THE CD-rom Learning appropriate use of antibiotics (PK/PD and guidelines): a CD-rom course for healthcare professionals.

25 MB of information … CONTENT OF THE CD-rom Learning appropriate use of antibiotics (PK/PD and guidelines): a CD-rom course for healthcare professionals.
Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 In Vitro/Animal Models to Support Dosage Selection: FDA Perspective.

Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 In Vitro/Animal Models to Support Dosage Selection: FDA Perspective.
PK/PD of Antibiotics in relation to resistance Otto Cars MD Department of Medical Sciences Infectious diseases Uppsala University Sweden.

PK/PD of Antibiotics in relation to resistance Otto Cars MD Department of Medical Sciences Infectious diseases Uppsala University Sweden.
Rational Dosing: The Use of Plasma Concentrations vs. Tissue Concentrations Hartmut Derendorf, PhD University of Florida.

Rational Dosing: The Use of Plasma Concentrations vs. Tissue Concentrations Hartmut Derendorf, PhD University of Florida.
8th ISAP Symposium Can PK/PD be used in everyday clinical practice? Francesco Scaglione Department of Pharmacology, Toxicology and Chemotherapy, University.

8th ISAP Symposium Can PK/PD be used in everyday clinical practice? Francesco Scaglione Department of Pharmacology, Toxicology and Chemotherapy, University.
Pharmacodynamics of Antimicrobials in Animal Models William A. Craig, M.D. University of Wisconsin-Madison.

Pharmacodynamics of Antimicrobials in Animal Models William A. Craig, M.D. University of Wisconsin-Madison.
Mutant Prevention Concentration and the Selection Window Hypothesis Karl Drlica, Xilin Zhao, and Tao Lu Public Health Research Institute Newark, NJ.

Mutant Prevention Concentration and the Selection Window Hypothesis Karl Drlica, Xilin Zhao, and Tao Lu Public Health Research Institute Newark, NJ.
General Principles of Antimicrobial Therapy. Concept #1: The guiding principle of antibiotic selection Antibiotic coverage should be kept to the narrowest.

General Principles of Antimicrobial Therapy. Concept #1: The guiding principle of antibiotic selection Antibiotic coverage should be kept to the narrowest.

Similar presentations

Ads by Google